Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of atherosclerotic coronary artery disease in tactical athletes.

American journal of preventive cardiology·2026
Same author

Resistance training in older adults: are the gains worth the strain?

American journal of preventive cardiology·2026
Same author

Sports Cardiology Care in the United States: Can We Fix Fractured Cardiac Care?

JACC. Advances·2026
Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026
Same author

Cardiovascular Risk Prediction Across the Spectrum of Measured Physical Activity.

Journal of the American College of Cardiology·2026
Same author

Voluntarily Stopping Eating and Drinking (VSED) With Hospice Support in America: A Case Series.

Journal of pain and symptom management·2026
Same journal

Correction: Assalve et al. Marine Algal Metabolites as Cellular Antioxidants: A Study of Caulerpin and Caulerpinic Acid in <i>Saccharomyces cerevisiae</i>. <i>Mar. Drugs</i> 2025, <i>23</i>, 338.

Marine drugs·2026
Same journal

Laurinterol, the Main <i>Smart Secondary Metabolite</i> Among Lauranes and Cyclolauranes.

Marine drugs·2026
Same journal

Red Light Enhances Biomass and Bioactive Compounds Through Photosynthetic Acclimation in <i>Anabaena variabilis</i>.

Marine drugs·2026
Same journal

Seaweed-Derived Extract Targets Porphyr'ageing to Modulate the Visible Signs of Aging in Human Skin.

Marine drugs·2026
Same journal

The Potential and Prospects of Marine Drugs in Intervening Nerve-Tumor Crosstalk.

Marine drugs·2026
Same journal

Amylimycins A-C, New Bacillomycin D Analogs from Marine-Derived <i>Bacillus amyloliquefaciens</i>.

Marine drugs·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K

Trabectedin in soft tissue sarcomas.

Bradley J Petek1, Elizabeth T Loggers2, Seth M Pollack3

  • 1University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA. bpetek@uw.edu.

Marine Drugs
|February 17, 2015
PubMed
Summary
This summary is machine-generated.

Trabectedin offers a new treatment option for metastatic soft tissue sarcoma, showing efficacy in various subtypes and settings. This drug provides a favorable toxicity profile for patients with advanced cancers.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K

Related Experiment Videos

Last Updated: Apr 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Soft tissue sarcomas are rare mesenchymal tumors with poor outcomes in metastatic disease.
  • Current treatments, like doxorubicin, have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the development and clinical application of trabectedin for treating soft tissue sarcomas.
  • To highlight trabectedin's efficacy and safety in various treatment settings.

Main Methods:

  • Review of phase II trials and clinical data on trabectedin in soft tissue sarcoma.
  • Analysis of trabectedin's mechanisms of action, including DNA binding and cell cycle interference.

Main Results:

  • Trabectedin demonstrates activity in anthracycline- and alkylating agent-resistant soft tissue sarcomas.
  • Recent studies show trabectedin's comparable progression-free survival to doxorubicin in first-line treatment.
  • Significant efficacy observed in liposarcoma and leiomyosarcoma subtypes with a favorable toxicity profile.

Conclusions:

  • Trabectedin is an effective treatment option for metastatic soft tissue sarcoma, particularly in resistant cases and specific subtypes.
  • Its approval in over 70 countries underscores its clinical significance and favorable safety profile.